BRPI0804091B8 - compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm - Google Patents

compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm

Info

Publication number
BRPI0804091B8
BRPI0804091B8 BRPI0804091A BRPI0804091A BRPI0804091B8 BR PI0804091 B8 BRPI0804091 B8 BR PI0804091B8 BR PI0804091 A BRPI0804091 A BR PI0804091A BR PI0804091 A BRPI0804091 A BR PI0804091A BR PI0804091 B8 BRPI0804091 B8 BR PI0804091B8
Authority
BR
Brazil
Prior art keywords
group
optionally substituted
hydrogen atom
tetrahydro
preparation
Prior art date
Application number
BRPI0804091A
Other languages
English (en)
Inventor
Dessinges Aimee
Goument Bertrand
Thollon Catherine
Peglion Jean-Louis
Vilaine Jean-Paul
Villeneuve Nicole
Caignard Pascal
Chimenti Stefano
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39323822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0804091(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0804091A2 publication Critical patent/BRPI0804091A2/pt
Publication of BRPI0804091B1 publication Critical patent/BRPI0804091B1/pt
Publication of BRPI0804091B8 publication Critical patent/BRPI0804091B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm. compostos de fórmula (i): na qual: - r1 representa um átomo de hidrogênio ou um grupo selecionado a partir de cicloalquila, benzila e alquila opcionalmente substituída, - r2, r3, r4 e r5 cada um representa um átomo de hidrogênio ou um grupo hidróxi, metila, -oso2r10, -cocr10 ou alcóxi opcionalmente substituído, ou r2 e r3, ou r3 e r4 ou r4 e r5, em conjunto, formam um grupo -o-(ch2)q-o-, -o-ch=ch-o- ou -o-ch=ch-, - r6, r7, r8 e r9 cada um representa um átomo de hidrogênio ou um alcóxi, ou r6 e r7, ou r7 e r8 ou r8 e r9, em conjunto, formam um grupo -o-(ch2)q-o-, - r10 representa um grupo selecionado a partir de c1-c6-alcóxi linear ou ramificado, nr11r'11 e alquila opcionalmente substituída, - r11 e r'11 cada um representa um átomo de hidrogênio ou um grupo alquila, ou r11 e r'11, em conjunto com o átomo de nitrogênio que os porta, formam um heterociclo contendo nitrogênio, monocíclico ou bicíclico, opcionalmente substituído, - x representa o, nh ou ch2, - m e p cada um representa o ou 1, - n e q cada um representa 1 ou 2, em forma racêmica ou na forma de isômeros ópticos e também sais de adição dos mesmos com um ácido farmaceuticamente aceitável. medicamentos.
BRPI0804091A 2007-09-11 2008-09-11 compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm BRPI0804091B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706346 2007-09-11
FR0706346A FR2920773B1 (fr) 2007-09-11 2007-09-11 Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number Publication Date
BRPI0804091A2 BRPI0804091A2 (pt) 2009-05-05
BRPI0804091B1 BRPI0804091B1 (pt) 2020-09-29
BRPI0804091B8 true BRPI0804091B8 (pt) 2021-05-25

Family

ID=39323822

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0804091A BRPI0804091B8 (pt) 2007-09-11 2008-09-11 compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm

Country Status (45)

Country Link
US (1) US8076325B2 (pt)
EP (1) EP2036892B1 (pt)
JP (1) JP4932805B2 (pt)
KR (1) KR101078076B1 (pt)
CN (1) CN101386594B (pt)
AP (1) AP2384A (pt)
AR (1) AR068386A1 (pt)
AT (1) ATE460401T1 (pt)
AU (1) AU2008207585B2 (pt)
BR (1) BRPI0804091B8 (pt)
CA (1) CA2639349C (pt)
CL (1) CL2008002654A1 (pt)
CO (1) CO6020016A1 (pt)
CR (1) CR10229A (pt)
CU (1) CU23706B7 (pt)
CY (1) CY1110034T1 (pt)
DE (1) DE602008000786D1 (pt)
DK (1) DK2036892T3 (pt)
EA (1) EA014756B1 (pt)
EC (1) ECSP088731A (pt)
ES (1) ES2342511T3 (pt)
FR (1) FR2920773B1 (pt)
HK (1) HK1129667A1 (pt)
HN (1) HN2008001393A (pt)
HR (1) HRP20100259T1 (pt)
JO (1) JO2652B1 (pt)
MA (1) MA30315B1 (pt)
ME (1) ME00981B (pt)
MX (1) MX2008011164A (pt)
MY (1) MY143079A (pt)
NI (1) NI200800247A (pt)
NZ (1) NZ571143A (pt)
PA (1) PA8795301A1 (pt)
PE (1) PE20090620A1 (pt)
PL (1) PL2036892T3 (pt)
PT (1) PT2036892E (pt)
RS (1) RS51305B (pt)
SA (1) SA08290567B1 (pt)
SG (1) SG151172A1 (pt)
SI (1) SI2036892T1 (pt)
TW (1) TWI374029B (pt)
UA (1) UA100003C2 (pt)
UY (1) UY31305A1 (pt)
WO (1) WO2009066041A2 (pt)
ZA (1) ZA200807586B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
FR2984319B1 (fr) * 2011-12-20 2013-12-27 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2984320B1 (fr) * 2011-12-20 2013-11-29 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2988720B1 (fr) * 2012-03-27 2014-03-14 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
TWI654180B (zh) 2012-06-29 2019-03-21 美商艾佛艾姆希公司 殺真菌之雜環羧醯胺
FR3003859B1 (fr) * 2013-03-26 2015-03-13 Servier Lab "procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine"
WO2015009534A2 (en) 2013-07-16 2015-01-22 Allergan, Inc. Hcn inhibitors affecting ganglion cell function and visual function
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018196782A1 (en) * 2017-04-27 2018-11-01 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
CN112724001B (zh) * 2019-10-28 2022-12-13 鲁南制药集团股份有限公司 一种伊伐布雷定手性中间体化合物
CN113372273B (zh) * 2020-03-10 2023-05-09 鲁南制药集团股份有限公司 一种伊伐布雷定中间体化合物iv
CN113372274B (zh) * 2020-03-10 2023-03-24 鲁南制药集团股份有限公司 一种伊伐布雷定的制备方法
MX2024001504A (es) * 2021-08-31 2024-02-27 Eisai R&D Man Co Ltd Metodo para producir un derivado de piridina monociclico.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8707120D0 (en) * 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
JPH02193971A (ja) * 1989-01-20 1990-07-31 Yamanouchi Pharmaceut Co Ltd トリ置換―２，３，４，５―テトラヒドロベンズアゼピン誘導体とその中間体
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
EP0700389A1 (en) * 1993-05-27 1996-03-13 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894826B1 (fr) 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
HK1129667A1 (pt) 2009-12-04
SI2036892T1 (sl) 2010-06-30
JP4932805B2 (ja) 2012-05-16
CN101386594B (zh) 2012-05-16
TWI374029B (en) 2012-10-11
FR2920773A1 (fr) 2009-03-13
UA100003C2 (ru) 2012-11-12
HRP20100259T1 (hr) 2010-06-30
HN2008001393A (es) 2011-05-11
MA30315B1 (fr) 2009-04-01
US20090069296A1 (en) 2009-03-12
RS51305B (sr) 2010-12-31
PL2036892T3 (pl) 2010-08-31
AU2008207585B2 (en) 2013-08-22
CO6020016A1 (es) 2009-03-31
SA08290567B1 (ar) 2011-06-22
KR20090027164A (ko) 2009-03-16
MX2008011164A (es) 2009-03-10
BRPI0804091B1 (pt) 2020-09-29
JO2652B1 (en) 2012-06-17
EA200801828A3 (ru) 2009-08-28
FR2920773B1 (fr) 2009-10-23
ATE460401T1 (de) 2010-03-15
CA2639349C (fr) 2011-03-22
CN101386594A (zh) 2009-03-18
CU23706B7 (es) 2011-10-05
WO2009066041A3 (fr) 2009-12-17
AP2384A (en) 2012-03-21
DE602008000786D1 (de) 2010-04-22
PT2036892E (pt) 2010-05-10
DK2036892T3 (da) 2010-06-07
CL2008002654A1 (es) 2009-03-20
EP2036892B1 (fr) 2010-03-10
BRPI0804091A2 (pt) 2009-05-05
ZA200807586B (en) 2011-04-28
EA200801828A2 (ru) 2009-04-28
ECSP088731A (es) 2008-10-31
NZ571143A (en) 2010-04-30
SG151172A1 (en) 2009-04-30
CY1110034T1 (el) 2015-01-14
EA014756B1 (ru) 2011-02-28
ME00981B (me) 2012-06-20
EP2036892A1 (fr) 2009-03-18
WO2009066041A2 (fr) 2009-05-28
ES2342511T3 (es) 2010-07-07
AR068386A1 (es) 2009-11-11
UY31305A1 (es) 2008-10-31
TW200918076A (en) 2009-05-01
MY143079A (en) 2011-02-28
CU20080165A7 (es) 2011-03-21
CR10229A (es) 2008-11-26
AU2008207585A1 (en) 2009-03-26
US8076325B2 (en) 2011-12-13
AP2008004589A0 (en) 2008-08-31
PA8795301A1 (es) 2009-04-23
JP2009108032A (ja) 2009-05-21
CA2639349A1 (fr) 2009-03-11
PE20090620A1 (es) 2009-05-30
KR101078076B1 (ko) 2011-10-28
NI200800247A (es) 2011-01-10

Similar Documents

Publication Publication Date Title
BRPI0804091B8 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
BRPI0519287A2 (pt) derivados de amida
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
BR112014009717A2 (pt) "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica"
BRPI0713923B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0408338A (pt) piperidinas substituìdas como novos inibidores de mdm2-p53
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
BRPI0111142C1 (pt) utilização de derivados de biguanida ou sais farmaceuticamente aceitáveis dos mesmos para fabricação de medicamento tendo um efeito cicatrizante
BR112021019817A2 (pt) Compostos de pirrol
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
BRPI0519210A2 (pt) macrocilos de sulfonamido como inibidores de tie2 e os sais destes, uma composiÇço farmacÊutica compreendendo estes compostos, o mÉtodo de preparar e o uso destes
RU2013145799A (ru) Новое производное октагидротиенохинолина, фармацевтическая композиция, содержащая производное, и их применение
BR0104471A (pt) Compostos de ciclobutenodiona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos
BR0308807A (pt) Compostos tiazol-2-il-imina como inibidores de pde-7
AR060979A1 (es) Compuestos de tiofeno de bencimidazol
BRPI0601263A (pt) compostos de piperazina, processo para sua preparação e composições farmacêuticas contendo-os
BRPI0507511A (pt) composto, uso de um composto, composição farmacêutica,e, processo para preparar um composto

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2739 DE 04-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.